ABOS Relative Valuation
ABOS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ABOS is overvalued; if below, it's undervalued.
Historical Valuation
Acumen Pharmaceuticals Inc (ABOS) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -7.12. The fair price of Acumen Pharmaceuticals Inc (ABOS) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：1.82
Fair
-1.32
PE
1Y
3Y
5Y
-0.14
EV/EBITDA
Acumen Pharmaceuticals Inc. (ABOS) has a current EV/EBITDA of -0.14. The 5-year average EV/EBITDA is -2.06. The thresholds are as follows: Strongly Undervalued below -16.71, Undervalued between -16.71 and -9.39, Fairly Valued between 5.26 and -9.39, Overvalued between 5.26 and 12.59, and Strongly Overvalued above 12.59. The current Forward EV/EBITDA of -0.14 falls within the Historic Trend Line -Fairly Valued range.
-0.17
EV/EBIT
Acumen Pharmaceuticals Inc. (ABOS) has a current EV/EBIT of -0.17. The 5-year average EV/EBIT is -1.80. The thresholds are as follows: Strongly Undervalued below -14.67, Undervalued between -14.67 and -8.23, Fairly Valued between 4.64 and -8.23, Overvalued between 4.64 and 11.07, and Strongly Overvalued above 11.07. The current Forward EV/EBIT of -0.17 falls within the Historic Trend Line -Fairly Valued range.
0.00
PS
Acumen Pharmaceuticals Inc. (ABOS) has a current PS of 0.00. The 5-year average PS is 112.41. The thresholds are as follows: Strongly Undervalued below -813.57, Undervalued between -813.57 and -350.58, Fairly Valued between 575.41 and -350.58, Overvalued between 575.41 and 1038.40, and Strongly Overvalued above 1038.40. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-0.91
P/OCF
Acumen Pharmaceuticals Inc. (ABOS) has a current P/OCF of -0.91. The 5-year average P/OCF is -4.81. The thresholds are as follows: Strongly Undervalued below -14.23, Undervalued between -14.23 and -9.52, Fairly Valued between -0.10 and -9.52, Overvalued between -0.10 and 4.61, and Strongly Overvalued above 4.61. The current Forward P/OCF of -0.91 falls within the Historic Trend Line -Fairly Valued range.
-1.12
P/FCF
Acumen Pharmaceuticals Inc. (ABOS) has a current P/FCF of -1.12. The 5-year average P/FCF is -4.73. The thresholds are as follows: Strongly Undervalued below -15.87, Undervalued between -15.87 and -10.30, Fairly Valued between 0.84 and -10.30, Overvalued between 0.84 and 6.41, and Strongly Overvalued above 6.41. The current Forward P/FCF of -1.12 falls within the Historic Trend Line -Fairly Valued range.
Acumen Pharmaceuticals Inc (ABOS) has a current Price-to-Book (P/B) ratio of 1.31. Compared to its 3-year average P/B ratio of 0.84 , the current P/B ratio is approximately 56.78% higher. Relative to its 5-year average P/B ratio of 0.90, the current P/B ratio is about 46.40% higher. Acumen Pharmaceuticals Inc (ABOS) has a Forward Free Cash Flow (FCF) yield of approximately -101.13%. Compared to its 3-year average FCF yield of -56.69%, the current FCF yield is approximately 78.41% lower. Relative to its 5-year average FCF yield of -40.32% , the current FCF yield is about 150.84% lower.
1.31
P/B
Median3y
0.84
Median5y
0.90
-101.13
FCF Yield
Median3y
-56.69
Median5y
-40.32
Competitors Valuation Multiple
The average P/S ratio for ABOS's competitors is 235.25, providing a benchmark for relative valuation. Acumen Pharmaceuticals Inc Corp (ABOS) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of ABOS increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of ABOS in the past 1 year is driven by Unknown.
People Also Watch
FRD
Friedman Industries Inc
19.53USD
0.62%
CRDL
Cardiol Therapeutics Inc
1.01USD
0.00%
SUNS
Sunrise Realty Trust Inc
9.435USD
-0.58%
SDST
Stardust Power Inc
3.67USD
-1.61%
RECT
Rectitude Holdings Ltd
1.69USD
-1.74%
MGX
Metagenomi Inc
1.785USD
-0.83%
LNSR
LENSAR Inc
11.95USD
3.64%
MDXH
MDxHealth SA
3.33USD
-0.30%
HNNA
Hennessy Advisors Inc
9.75USD
-0.31%
Frequently Asked Questions
Is Acumen Pharmaceuticals Inc (ABOS) currently overvalued or undervalued?
Acumen Pharmaceuticals Inc (ABOS) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -7.12. The fair price of Acumen Pharmaceuticals Inc (ABOS) is between NaN to NaN according to relative valuation methord.
What is Acumen Pharmaceuticals Inc (ABOS) fair value?
ABOS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Acumen Pharmaceuticals Inc (ABOS) is between NaN to NaN according to relative valuation methord.
How does ABOS's valuation metrics compare to the industry average?
The average P/S ratio for ABOS's competitors is 235.25, providing a benchmark for relative valuation. Acumen Pharmaceuticals Inc Corp (ABOS) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Acumen Pharmaceuticals Inc (ABOS) as of Jan 08 2026?
As of Jan 08 2026, Acumen Pharmaceuticals Inc (ABOS) has a P/B ratio of 1.31. This indicates that the market values ABOS at 1.31 times its book value.
What is the current FCF Yield for Acumen Pharmaceuticals Inc (ABOS) as of Jan 08 2026?
As of Jan 08 2026, Acumen Pharmaceuticals Inc (ABOS) has a FCF Yield of -101.13%. This means that for every dollar of Acumen Pharmaceuticals Inc’s market capitalization, the company generates -101.13 cents in free cash flow.
What is the current Forward P/E ratio for Acumen Pharmaceuticals Inc (ABOS) as of Jan 08 2026?
As of Jan 08 2026, Acumen Pharmaceuticals Inc (ABOS) has a Forward P/E ratio of -1.32. This means the market is willing to pay $-1.32 for every dollar of Acumen Pharmaceuticals Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Acumen Pharmaceuticals Inc (ABOS) as of Jan 08 2026?
As of Jan 08 2026, Acumen Pharmaceuticals Inc (ABOS) has a Forward P/S ratio of 0.00. This means the market is valuing ABOS at $0.00 for every dollar of expected revenue over the next 12 months.